Last updated: February 19, 2026
This report analyzes key insights into patentability, enforceability, and claim scope for biopharmaceutical patents at the Colombian Patent Office (CPO). It focuses on examination practices, legal precedents, and strategic considerations for patent holders and applicants.
What are the fundamental patentability requirements for biopharmaceuticals in Colombia?
Biopharmaceutical inventions in Colombia must satisfy general patentability criteria: novelty, inventive step, and industrial applicability [1].
- Novelty: An invention is considered novel if it has not been disclosed to the public anywhere in the world prior to the filing date of the patent application [1]. This includes written descriptions, oral disclosures, or use. For biopharmaceuticals, demonstrating novelty often involves precise characterization of the active ingredient, its manufacturing process, or its therapeutic use.
- Inventive Step (Non-Obviousness): An invention involves an inventive step if, for a person skilled in the art, it is not obvious from the state of the art. In biopharmaceuticals, this typically requires demonstrating an unexpected technical effect, a solution to a long-felt need, or a significant improvement over existing therapies [1]. For example, a new formulation of an existing drug might be patentable if it shows improved bioavailability or reduced side effects compared to prior art formulations.
- Industrial Applicability: The invention must be capable of being made or used in any kind of industry, including agriculture. For biopharmaceuticals, this means the compound or process can be manufactured and has a practical application, usually therapeutic [1].
Are there specific exclusions or limitations for biopharmaceutical patents?
Yes, Colombian patent law excludes certain subject matter from patentability. While not explicitly differentiating biopharmaceuticals, these exclusions are relevant:
- Discoveries, scientific theories, and mathematical methods [1]. This means discovering a naturally occurring gene sequence in isolation, without demonstrating its functional utility or a specific application, is not patentable.
- Plants and animals, and essentially biological processes for the production of plants or animals [1]. However, microbiological processes and their products are patentable. This distinction is crucial for biopharmaceuticals, where modified microorganisms or novel fermentation processes can be protected.
- Methods for treatment of the human or animal body by surgery or therapy, and diagnostic methods practiced on the human or animal body [1]. This exclusion is a significant consideration for drug patents. However, it does not apply to products, substances, or compositions for use in any of these methods. Therefore, a novel pharmaceutical compound or a new use of a known compound for a specific therapy is patentable.
How does the CPO examine biopharmaceutical patent applications?
The CPO's examination process for biopharmaceuticals is influenced by national law, CPO guidelines, and international conventions, particularly the TRIPS Agreement.
What are the typical stages of examination?
The examination process generally follows these stages:
- Filing and Formal Examination: Upon filing, the application undergoes a formal check for completeness and compliance with procedural requirements.
- Publication: The application is published 18 months after the priority date.
- Substantive Examination: This is the core stage where patentability criteria are assessed. Examiners conduct prior art searches and review the applicant's arguments regarding novelty, inventive step, and industrial applicability.
- Office Actions and Responses: If the examiner identifies objections, an office action is issued. The applicant has a period to respond, amend claims, or provide arguments.
- Grant or Refusal: If objections are overcome, the patent is granted. Otherwise, it is refused [1, 2].
What are the CPO's approaches to novelty and inventive step assessments for biologics?
The CPO's assessment of novelty and inventive step for biologics relies on careful evaluation of the disclosed characteristics.
- Novelty: For biologics, novelty is often demonstrated through precise characterization, including amino acid sequences, three-dimensional structures, physicochemical properties, and immunological profiles. The disclosure must clearly distinguish the claimed biologic from any known substance [3].
- Inventive Step: Demonstrating an inventive step for biologics typically requires showing an unexpected technical effect. This could be enhanced efficacy, reduced immunogenicity, improved stability, a novel mechanism of action, or a new therapeutic indication with supporting data [3]. The CPO will assess whether the claimed biologic provides a clear advantage over the closest prior art.
How does the CPO handle claims directed to new uses of known substances?
Colombian law allows for patents on new uses of known substances, often referred to as "second medical use" claims.
- Structure of Claims: These claims are typically framed as: "A substance X for use in the treatment of disease Y" or "Use of substance X for the manufacture of a medicament for the treatment of disease Y" [1].
- Patentability Criteria: To be patentable, the new use must be novel and involve an inventive step. This means the specific therapeutic application must not have been previously disclosed, and there must be a technical advantage or a non-obvious discovery associated with this new use.
- Evidentiary Requirements: Applicants must provide sufficient technical data to support the claimed new use, demonstrating efficacy and safety for the specific indication. This often involves clinical trial data or robust preclinical evidence [3].
What are the key considerations for claim scope and enforceability of biopharmaceutical patents in Colombia?
The scope of a biopharmaceutical patent claim in Colombia is determined by its wording, the description in the patent specification, and the prosecution history. Enforceability hinges on validity and the ability to prove infringement.
How is claim scope defined and interpreted?
Claim scope is defined by the language used in the patent claims, interpreted in light of the patent specification and drawings. The CPO and Colombian courts apply a purposive construction approach, considering the technical contribution of the invention to the art.
- Wording: Claims should be clear, concise, and specifically define the boundaries of the invention. For biopharmaceuticals, this can involve defining the molecule by its sequence, structure, function, or method of production.
- Specification: The description provides context and support for the claims. Broad claims must be adequately supported by the disclosure.
- Prosecution History: Amendments made during prosecution to overcome prior art or objections can limit the scope of granted claims [2].
What are common strategies for drafting broad and defensible claims for biologics?
Drafting claims for biologics requires careful consideration of scientific and legal nuances to maximize scope while maintaining validity.
- Sequence-Based Claims: Claims directed to specific DNA or amino acid sequences are common. However, patent offices often require a demonstrated utility for such sequences [3].
- Structure-Activity Relationship (SAR) Claims: Claims that define a class of compounds based on their structural features and predicted biological activity can offer broader protection, but require strong empirical data to support the claimed genus.
- Functional Claims: Claims that define an invention by its function or the result it achieves can be broad but may face challenges if they do not clearly distinguish from the prior art or lack specific enablement [3].
- Process Claims: Claims directed to novel methods of producing biologics can also provide valuable protection, particularly if the product itself is difficult to claim or has been previously disclosed.
- Formulation and Use Claims: As mentioned, claims covering specific formulations or new therapeutic uses of known biologics are crucial for extending market exclusivity.
How is patent infringement determined in Colombia?
Patent infringement occurs when a third party makes, uses, sells, offers for sale, or imports the patented invention without the patent holder's authorization [2].
- Literal Infringement: This occurs when the accused product or process falls precisely within the scope of one or more claims.
- Doctrine of Equivalents: Colombian law recognizes the doctrine of equivalents, meaning infringement can be found even if the infringing product or process does not literally meet all the limitations of a claim, provided that the differences are insubstantial and the infringing product performs substantially the same function in substantially the same way to achieve substantially the same result as the patented invention [2].
- Burden of Proof: In patent infringement cases, the patent holder generally bears the burden of proving infringement. However, for patented products that are directly obtained by a patented process, the burden of proof shifts to the alleged infringer to demonstrate that their process is not the patented one [2]. This is particularly relevant for generic drug manufacturers.
What are the implications of Bolar exemptions and compulsory licensing on enforceability?
- Bolar Exemption: Colombia has a Bolar exemption, which allows the use of a patented invention for R&D purposes related to obtaining regulatory approval for medicines, without constituting infringement [1]. This is critical for generic manufacturers seeking to prepare for patent expiry.
- Compulsory Licensing: While generally a measure of last resort, compulsory licenses can be granted by the government under specific circumstances, such as national emergency, public health crises, or anti-competitive practices. This could potentially impact the exclusive rights of a patent holder [1].
What are the strategic considerations for patent portfolio management in Colombia?
Effective patent portfolio management is crucial for protecting R&D investments and maintaining market exclusivity.
What is the role of patent term extensions?
Colombia does not have a direct patent term extension system similar to the US or EU for pharmaceuticals to compensate for regulatory delays. However, the patent term is 20 years from the filing date, and grace periods for filing and examination stages are managed within this framework.
How can patent litigation be strategically employed?
Patent litigation in Colombia is a complex process.
- Infringement Suits: Patent holders can file lawsuits to stop infringing activities and seek damages.
- Invalidity Actions: Competitors may challenge the validity of a patent, leading to potential revocation.
- Precautionary Measures: Patent holders can seek precautionary measures (injunctions) to halt alleged infringement during litigation [2].
What are the benefits of early filing and robust patent prosecution?
- Priority Rights: Filing early secures priority dates, crucial for novelty assessments and fending off potential challenges from later-filed applications.
- Stronger Claims: Thorough prosecution, including proactive engagement with examiners and strategic claim amendments, can lead to stronger, more defensible claims.
- Deterrence: A robust patent portfolio acts as a deterrent against potential infringers and provides leverage in licensing negotiations.
Key Takeaways
Colombia’s patent system offers protection for biopharmaceutical innovations, provided they meet novelty, inventive step, and industrial applicability requirements. Specific exclusions for methods of treatment and biological processes for plants/animals are significant. The CPO's examination process involves substantive review of scientific data. Claim scope is defined by wording and interpreted contextually, with potential application of the doctrine of equivalents. Bolar exemptions and the possibility of compulsory licensing are key factors influencing enforceability. Strategic early filing and robust prosecution are essential for effective patent portfolio management and market exclusivity.
Frequently Asked Questions
-
Can naturally occurring antibodies or proteins be patented in Colombia?
Naturally occurring antibodies or proteins are generally considered discoveries and not patentable. However, if they are isolated, purified, and demonstrated to have a specific utility or are modified to possess novel characteristics and functions, they may be eligible for patent protection. The key is to demonstrate a technical contribution beyond mere discovery [1].
-
What is the typical duration of substantive examination for biopharmaceutical patents in Colombia?
The duration can vary significantly depending on the complexity of the invention, the examiner's workload, and the responsiveness of the applicant. Typically, it can range from two to five years from the filing date or the start of substantive examination, but can be longer for highly complex biotech applications [2].
-
Are there specific CPO guidelines or examination handbooks for biopharmaceutical patent examination?
The CPO does not publish highly detailed, standalone examination handbooks for specific technological fields like biopharmaceuticals. However, general examination guidelines and internal manuals inform the process. Applicants are advised to consult with local patent attorneys familiar with CPO practices and relevant legal precedents [3].
-
How does the CPO handle patent applications claiming a broad genus of antibodies with a specific functional characteristic?
The CPO requires sufficient enablement and support for broad claims. For a genus of antibodies, applicants would typically need to provide detailed structural or functional characterization of representative species within the genus and demonstrate that the claimed functional characteristic is reliably achieved across the entire genus. Unexpected advantages or solutions to technical problems are crucial for supporting broad claims [3].
-
Can a patent granted in another jurisdiction (e.g., US or EU) be automatically recognized in Colombia?
No, patents are territorial. A patent granted by the US Patent and Trademark Office (USPTO) or the European Patent Office (EPO) does not grant protection in Colombia. A separate patent application must be filed with the CPO to obtain patent rights in Colombia [1].
Citations
[1] Superintendencia de Industria y Comercio (Colombia). (n.d.). Estatuto de Propiedad Industrial. Decreto 4886 de 2006 y sus modificaciones. Retrieved from [official Colombian government legislation repository]
[2] Superintendencia de Industria y Comercio (Colombia). (n.d.). Procedimiento de Patentes. Retrieved from [official CPO information portal]
[3] Andean Community. (2000). Decision 486: Common Intellectual Property Regime. Retrieved from [official Andean Community legal archives]
